Risk-Adapted Treatment Of Et & Pv

Risk-adapted treatment of ET & PV

VJHemOnc – Video Journal of Hematology & HemOnc

Understanding High-Risk vs Low-Risk Disease in PV, ET & MF

Patient Empowerment Network

An Overview of ET, PV and MF Treatment Options

Patient Empowerment Network

Indication for cytoreductive therapy in ET and PV: Do we have it right?

Development of long-acting interferon as new therapy for PV and ET

Risk-Adapted Treatment in Myelofibrosis: JAK Inhibitors and Novel Combination Therapies

PeerView Oncology

Why MPNs Transform to AML

What Are Treatment Options for Essential Thrombocythemia (ET) & Polycythemia Vera (PV)?

Patient Empowerment Network

How Are ET, PV and Myelofibrosis Monitored?

Patient Empowerment Network

Treatment goals in Essential Thrombocythemia and Polycythemia vera

Upcoming agents in ET and PV

VJHemOnc – Video Journal of Hematology & HemOnc

Risk Stratification and the Management of Patients With PV

Targeted Oncology

Available Treatment Options for Patients With PV

Targeted Oncology

Ropeginterferon Alfa-2b for the treatment of low-risk patients with polycythemia vera

Long-acting interferon: What is the difference?

Srdan Verstovsek, MD, PhD: The Risk of Thrombosis in PV

Current therapy options and clinical outcomes analysis in patients with PV

Assessment of novel treatment options for patients with PV

Dr. Mascarenhas on the MPD-RC 112 Study in PV and Essential Thrombocythemia

New guidelines for the treatment and management of polycythemia vera

VJHemOnc – Video Journal of Hematology & HemOnc